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Abstract Patient-centeredness has become an acknowl-
edged hallmark of not only high-quality health care but also
high-quality drug development. Biopharmaceutical compa-
nies are actively seeking to be more patient-centric in drug
research and development by involving patients in identifying
target disease conditions, participating in the design of, and
recruitment for, clinical trials, and disseminating study
results. Drug safety departments within the biopharmaceuti-
cal industry are at a similar inflection point. Rising rates of per
capita prescription drug use underscore the importance of
having robust pharmacovigilance systems in place to detect
and assess adverse drug reactions (ADRs). At the same time,
the practice of pharmacovigilance is being transformed by a
host of recent regulatory guidances and related initiatives
which emphasize the importance of the patient’s perspective
in drug safety. Collectively, these initiatives impact the full
range of activities that fall within the remit of pharmacovig-
ilance, including ADR reporting, signal detection and eval-
uation, risk management, medication error assessment,
benefit–risk assessment and risk communication. Examples
include the fact that manufacturing authorization holders are
now expected tomonitor all digital sources under their control
for potential reports of ADRs, and the emergence of new
methods for collecting, analysing and reporting patient-gen-
erated ADR reports for signal detection and evaluation pur-
poses. A drug safety department’s ability to transition
successfully into a more patient-centric organization will
depend on three defining attributes: (1) a patient-centered
culture; (2) deployment of a framework to guide patient
engagement activities; and (3) demonstrated proficiency in
patient-centered competencies, including patient engage-
ment, risk communication and patient preference assessment.
Whether, and to what extent, drug safety departments
embrace the new patient-centric imperative, and the methods
and processes they implement to achieve this end effectively
and efficiently, promise to become distinguishing factors in
the highly competitive biopharmaceutical industry landscape.
Key Points
Patient-centeredness has become an acknowledged
hallmark of not only high-quality health care but also
high-quality drug development.
Recent patient-centric regulatory and related
initiatives are transforming the form and function of
the pharmacovigilance function within the
biopharmaceutical industry.
To meet this patient-centric imperative successfully,
pharmacovigilance departments will need to develop
a more patient-centered culture, use a framework-
driven approach to patient engagement and become
proficient in a range of patient-centered competencies.
1 Introduction
Patient-centeredness has become an acknowledged
hallmark of not only high-quality health care but also
high-quality drug development [1, 2]. Biopharmaceutical
companies are actively seeking to be more patient-centric
in drug research and development by involving patients in
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Table 1 Examples of key recent patient-centric initiatives affecting pharmaceutical drug safety
Drug safety domain Title Description
Adverse event reporting Directive 2010/84/EU amending Pharmacovigilance
Directive 2001/83/EC on the Community code relative
to medicinal products for use
Implementation of EU pharmacovigilance legislation
2012 expanding direct patient reporting of suspected
ADRs throughout the EU
Regulation (EU) 1235/2010 amending, as regards
pharmacovigilance of medicinal products for human
use, Regulation (EC) No. 726/2004 laying down
Community procedures for the authorisation and
supervision of medicinal products for human and
veterinary use and establishing a European Medicines
Agency and Regulation (EC) 1394/2007 on advanced
therapy medicinal products
European Medicines Agency (EMA). Guideline on Good
Pharmacovigilance Practices (GVP) Module VI:
Management and Reporting of Adverse Reactions to
Medicinal Products EMA/542040/2014 (2012)
Guidance outlines responsibilities for MAHs to:
(a) Monitor and screen internet sites and all forms of
digital media under their management or responsibility
for potential reports of suspected ADRs. The frequency
of the screening should allow for potential valid
individual case report forms to be reported to the health
authorities within the appropriate reporting timeframe,
based on the date on which the information was posted
on the internet site/digital medium
(b) Utilize their websites to facilitate the collection of
reports of suspected adverse reactions
Innovative Medicines Initiative (IMI) Web–Recognizing
Adverse Drug Reactions (Web-RADR) Consortium
(2014–2017)
The project’s goals are to:
(a) Develop robust text-mining techniques for analysis of
social media data for patient reports of potential
suspected ADRs to complement existing methods of
adverse event signal detection
(b) Develop and pilot a mobile app to facilitate patient
reporting of suspected ADRs
US National Cancer Institute’s Patient-Reported
Outcomes Version of the Common Terminology
Criteria for Adverse Events (PRO-CTCAE) Initiative
(2010)
The project goal was to develop a library of patient-
reported outcomes to supplement CTCAE reporting to
enable standard capture of patient-reported safety data
in clinical trials
Benefit–risk assessment Food and Drug Administration (FDA). Submission,
Review in PMAs, HDE Applications, and De Novo
Requests, and Inclusion in Device Labeling
The guidance describes scientific methods for sponsors to
use in collecting patient preference data on medicinal
devices, and how to submit such data in filing and
labellingDraft Guidance for Industry, Food and Drug
Administration Staff, and Other Stakeholders (May 18,
2015)
International Conference on Harmonisation (ICH) of
Technical Requirements for Registration of
Pharmaceuticals for Human Use. ICH Harmonised
Tripartite Guideline: M4E(R2) (effective 2016)
The guidance specifies inclusion of patient preference
data in the Clinical Overview Section 2.5.6 of the
Common Technical Document at the time of filing for
marketing authorization
IMI-2 Consortium on Patient Perspective Elicitation on
Benefits and Risks of Medicinal Products,
Supplementing Benefit-Risk Assessments by
Regulators and HTAs from Development through the
Entire Life Cycle (2015–2020)
The project goal is to develop recommendations with the
view of supporting the development of guidance for
industry, regulators and HTA bodies on how and when
in the product life cycle to consider patient perspectives
on benefits and risks of medicinal products to inform
the decision-making process by regulators and HTA
bodies
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identifying target disease conditions; participating in the
design of, and recruitment for, clinical trials; and dissem-
inating study results [3, 4].
Drug safety departments within the biopharmaceutical
industry are at a similar inflection point. On the one hand,
rising rates of per capita prescription drug use underscore
the importance of having robust pharmacovigilance sys-
tems in place to detect and assess adverse drug reactions
(ADRs) [4]. At the same time, both the process and the
practice of pharmacovigilance are being transformed by a
host of patient-centric trends [5]. Given the critical role
patients have to play in safe and appropriate use of medi-
cations, such a transformation is welcome, if not long
overdue [6–8]. This development, however, challenges
entrenched notions of the role and outputs of the pharma-
covigilance function. Nonetheless, marketing authorization
holders (MAHs) who are able to navigate this new terrain
proactively will benefit in terms of an enhanced patient
experience, improved patient safety outcomes and a com-
petitive advantage in the evolving regulatory and payer
landscape [4].
2 Patient-Centric Trends Affecting Drug Safety
‘Patient-centeredness’ or ‘patient-centricity’ is defined as
an understanding of the patient’s perspective concerning
his/her health condition and treatment experiences [9]. In
recent years, a series of regulatory guidances and other
initiatives have emerged, which effectively expand the
ability of drug safety departments to understand and
incorporate the patient’s perspective into pharmacovigi-
lance activities (Table 1). Collectively, these initiatives
impact the full range of activities that fall within the remit
of pharmacovigilance, including ADR reporting, signal
detection and evaluation, risk management, medication
error assessment, benefit–risk assessment and risk com-
munication. MAHs, for example, are now expected to
monitor all digital sources under their control for potential
reports of ADRs [10]. A new measurement system, the
Patient-Reported Outcomes Version of the Common Ter-
minology Criteria for Adverse Events (PRO-CTCAE), has
been developed to improve the precision and reliability of
patient-reported adverse events in clinical trials.
In addition, under the aegis of the Innovative Medicines
Initiative (IMI)’s Web-Recognizing Adverse Drug Reac-
tions (Web-RADR) project, robust methods have been
advanced for collecting, analysing and reporting patient-
generated ADR reports for signal detection and evaluation
purposes, and patient ADR reporting has been further
facilitated by the development of a mobile reporting app
[11–17].
The value of obtaining the patient perspective regarding
the benefit–risk profile of medicinal products is being
increasingly acknowledged by regulatory authorities. In
particular, recent revisions of the International Conference
on Harmonisation (ICH) M4E Guideline specify where to
include such data in the integrated benefit–risk section
of the clinical overview for marketing authorization
applications [18]. Relatedly, the US Food and Drug
Table 1 continued




EMA. Good practice guide on risk minimisation and
prevention of medication errors (2015)
The guidance outlines the responsibilities of sponsor to
conduct human factors testing during product
development
EMA. Good Pharmacovigilance Practices (GVP) Module
V: Risk Management. EMA/542040/2014 (2012)
The guidance requires sponsors to develop a lay
summary of the product Risk Management Plan for
public posting
EMA Guideline on GVP Module XVI: Risk
minimisation measures: selection of tools and
effectiveness indicators (Rev. 1)
The guidance outlines the responsibilities for sponsors to
obtain patient input into the design and testing of risk
minimization tools and programmes
EMA/542040/2014 (2012)
Council for International Organizations of Medical
Sciences (CIOMS) Working Group IX: Practical
Approaches to Risk Minimisation of Medicinal
Products (2014), Geneva
The guidance recommends that sponsors include patients
throughout the cycle of risk minimization planning,
implementation and evaluation
ADR adverse drug reaction, CIOMS Council for International Organizations of Medical Sciences, CTCAE Common Terminology Criteria for
Adverse Events, EC European Commission, EMA European Medicines Agency, EU European Union, FDA Food and Drug Administration,
GVP Good Pharmacovigilance Practices, HDE Humanitarian Device Exemption, HTA Health Technology Assessment, IMI Innovative
Medicines Initiative, ICH International Conference on Harmonisation, MAH marketing authorization holder, PMA Premarket Approval, PRO-
CTCAE Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events, Web-RADR Web–Recognizing Adverse
Drug Reactions
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Administration (FDA) has defined acceptable scientific
methods to use in obtaining patient preference data for
medical devices and has specified how such data can be
included not only in the marketing authorization applica-
tion but also in the label [19]. Both the FDA and the
European Medicines Agency (EMA) advocate for sponsors
to conduct human factors testing (‘simulated use testing’)
in patients in order to understand whether product
instructions for use are sufficiently clear [20, 21]. Simi-
larly, both the EMA and the Council for International
Organizations of Medical Sciences (CIOMS) recommend
that risk communication measures be tested for patient
comprehension and that patient input be elicited regarding
the feasibility and acceptability of any proposed ‘additional
risk minimization measures’ [22, 23].
Many of these recent developments impose new and/or
enhanced responsibilities on pharmacovigilance depart-
ments. Similarly, implementing these patient-centric ini-
tiatives may present new or added complexities and
challenges. A fundamental concern and challenge will be to
ensure that the privacy of patient data is adequately safe-
guarded. Other challenges include the need to apply sci-
entifically rigorous patient data collection methods that are
applicable across a range of healthcare settings (e.g. inpa-
tient versus outpatient), and to develop patient communi-
cation and training materials that are sensitive to
demographic, cultural and linguistic heterogeneity within
and across populations. Requests for patient input must be
appropriately balanced so as to avoid over-burdening
patients who are taking multiple drugs from different
MAHs. Not least, it will be important to continue supporting
advances in the science of patient preference assessment
such that these data can be used to inform regulatory
authority assessments of the product benefit–risk profile
and, potentially, incorporated into product labelling as well.
Significantly, however, these developments also offer
new opportunities for proactively engaging with patients
not only in the safety evidence generation process but also
for the purposes of supporting safe and appropriate product
use (Fig. 1). Such opportunities include use of eHealth
methods such as ‘gamification’ (video game-based tech-
niques that create virtual simulations of real-world use
scenarios) to reinforce safe use messaging and practices,
and use of animated text and graphics to convey drug
benefit–risk statistics [24, 25]. Similarly, new evaluative
techniques can be employed to determine the
Fig. 1 The patient journey: key potential points of engagement
between patients and drug safety. Source: Adapted with permission
from PatientsLikeMe from slide presented by S. Okun at ‘‘REMS
Impact on Healthcare Delivery System and Patient Access,’’ Food and
Drug Administration (FDA) Center for Drug Evaluation and Research
Public Workshop, October 5, 2015, Rockville, MD, Docket No. FDA-
2013-N-0502
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comprehensibility of patient-targeted safety information—
including, for example, the ‘teach-back method’, which
requires patients to describe, in their own words, their
understanding of the safety information [26].
3 Key Attributes of the Patient-Centered Drug
Safety Department
Drug safety departments that are able to successfully
transition into a more patient-centric organization will
possess three defining attributes or ‘hallmarks’. These
include (1) a patient-centered culture; (2) a framework to
guide patient engagement activities; and (3) being con-
versant in applying a range of patient engagement methods
and other patient-centered competencies. Strategic objec-
tives and supporting tactics that can assist in this transition
are outlined in Table 2.
3.1 A Culture of Patient-Centeredness
A key organizational attribute is a culture of patient-cen-
teredness, one that emphasizes the importance of under-
standing the patient’s needs and goals for treatment, and
the patient’s experience, or ‘journey’, in regard to illness
and medical therapies. Such a culture clearly explicates the
link between the patient and the work of individuals within
the pharmacovigilance organization. Among the possible
tactics that can be used to achieve a patient-centered cul-
ture, the most critical ones include senior management
support, alignment with a supportive governance structure,
establishment of performance metrics around patient
engagement and provision of ongoing training to ensure
that staff behaviours are consistent with a patient-centered
cultural norm.
3.2 A Framework for Patient Engagement
The purpose of a framework is to provide a systematic,
integrated, comprehensive and transparent process for
patient engagement, and to facilitate cross-functional col-
laboration and sharing of patient-generated data. A
framework outlines when, where and how patients are to be
engaged at different junctures in the pharmacovigilance
process, and the resources needed to achieve such
engagement [4]. A framework can also serve as the
linchpin that supports the development and implementation
of policies for patient engagement, training, and commu-
nicating and reinforcing normative expectations for what it
means to be an ‘activated’, empowered patient. Not least, a
patient engagement framework should also specify metrics
to evaluate both the quantity and the quality of patient
engagement at defined points throughout the product life
cycle.
Table 2 Strategic and tactical considerations for achieving a patient-centered drug safety organization
Strategy Tactics
Embed a patient-centered culture within the drug safety
organization
Orient core drug safety functions towards understanding and addressing patient
preferences, goals and priorities
Communicate the value of patient-generated information across the department,
as well as the larger organization
Support modifications in practice with changes in drug safety staff culture by:
Communicating a vision
Establishing accountability
Creating metrics to measure staff behaviour
Establishing a supportive governance structure and processes
Providing training
Develop a framework to engage with patients Internally: integrate patient engagement efforts with those patient engagement
initiatives occurring elsewhere in the larger organization
Establish metrics to measure progress and the degree of transparency in reaching
this goal, and to measure the quality and quantity of patient engagement
Externally: co-promote patient engagement with patient communities as a
sustainable and scalable commitment
Become proficient in applying patient-centered engagement
methods and other patient-centered competencies
Apply health literacy and numeracy principles in the development of labelling
and other patient-targeted materials for communicating safe and appropriate
use of medicinal drugs and devices, and benefit–risk information
Use eHealth tools to engage with patients to communicate/educate
Develop patient-targeted benefit–risk decision aids
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3.3 Proficiency in Patient Engagement Methods
The patient-centered pharmacovigilance department of the
future will also exhibit a number of key competencies
(Table 3). These competencies can be acquired by hiring
new professionals with relevant credentials, cultivating in-
house talent by investing in staff training, and/or out-
sourcing to vendors with the requisite types of expertise.
Examples of key competencies include fostering a patient-
centered ethos within the organization, increasing patient
access to understandable information via routine applica-
tion of health literacy principles in the development of
patient labelling and other patient-targeted risk communi-
cation materials, and the ability to obtain and integrate
patient perspectives and preferences into relevant aspects
of pharmacovigilance activities, such as product benefit–
risk assessment, and risk management planning and eval-
uation [27].
4 Conclusion
Patient-centricity is transforming the form and function of
pharmacovigilance. Partnering with patients to develop
new medicinal products and devices that meet patients’
needs under real-world use conditions will involve a
significant change in organizational culture. How drug
safety departments, as well as biopharmaceutical compa-
nies as a whole, grapple with addressing this new, patient-
centric imperative—and what methods and processes they
implement to achieve this end effectively and efficiently—
will be distinguishing factors in the highly competitive
industry landscape. While currently there is no consensus
regarding the optimal approach for engaging with patients,
drug safety departments that invest in developing an
internal patient-centered ‘ecosystem,’ including appropri-
ate infrastructure and competencies, will be well-posi-
tioned to embrace this new era.
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